What ASCO 2025 Means For The Future Of Oncology Trials

The ASCO 2025 Annual Meeting offered a look at the rapidly evolving oncology landscape, where innovation is reshaping research priorities, trial strategies, and global development approaches. For Novotech, the event served as both a scientific touchpoint and a valuable opportunity to engage directly with sponsors navigating new pressures, such as regulatory uncertainty, cost constraints, and increased demand for geographically diverse early-phase trials.

These conversations confirmed a growing need for CRO partners who not only deliver operational excellence but also provide strategic insights, regional expertise, and the flexibility to adapt to complex and evolving trial designs. As oncology development becomes increasingly complex, selecting a CRO with global capabilities and local agility is crucial for achieving long-term success. Novotech continues to invest in infrastructure, technology, and partnerships to help sponsors accelerate timelines and bring innovative therapies to patients worldwide. Explore how Novotech can support your oncology development with global reach and local precision.